Skip to main content
. 2009 Apr 14;100(10):1517–1522. doi: 10.1038/sj.bjc.6605031

Figure 1.

Figure 1

Classification of defined genetic abnormalities in solid tumours to optimise tumour response. Figure shows the three methods through which improved molecular classification of solid tumours is challenging the traditional approach to cytotoxic delivery (green font indicates theoretical or proven sensitivity and red font indicates resistance based on molecular aberration). Mutations (EGFR) or amplification (HER2) guides the use of EGFR tyrosine kinase inhibitors in NSCLC and breast cancer, respectively. Assessing whether genomic instability is an exploitable phenotype is currently under investigation (CINATRA: chromosomal instability and anti-tubulin response assessment) and new approaches evolving from molecular analysis of solid tumours may be directed towards activated pathways in solid tumours through the attenuation of Wnt and Hedgehog signalling. CIN=chromosomal instability, MMR=mismatch repair, CRC=colorectal cancer, mAb=monoclonal antibody, EGFR=epidermal growth factor receptor.